Ophthalmology

Review explores reducing corticosteroid use with immunomodulatory therapies.

Two-year retrospective study indicates need to tailor treatment strategy.

DME patients in non-interventional studies notably older than in RCTs.

The MD Magazine editors rounded up the 10 best stories from this month.

Researchers compared aflibercept, bevacizumab, and ranibizumab injections.

Despite good responses, patients dropped adalimumab treatment.

Researchers evaluated children with arthritis, uveitis, and both.

When standard treatment failed, adding adalimumab achieved remission in 64%.

Of the 3 regimens, monthly aflibercept produced the greatest gain in mean BCVA.

In a long-term study, surgery was better than medical care alone for diabetes.

A combination of mycophenolate mofetil and corticosteroid showed benefit.

People with noninfectious uveitis tend to have low vitamin D levels.

Elevated IOP is uncommon in uveitis, but showed up in a pair of Zika patients.

Uveitis patients age ≥55 years are less likely to have large drusen than others.

Using red-channel separation gives a better picture in diagnosis of DME.

Between 2012 and 2015, pod-related eye burns among toddlers increased 3000%.

Screen for morphological risk factors for an RPE tear before each injection.

The MD Magazine editors rounded up the 10 best stories from January—did you read them all?

Report underscores the need to act quickly, refer patients with eye problems.

Evidence of the correlation is strong, but the exact cause remains unverified.

T. gondii is one of the most common causes of infectious posterior uveitis.

An association is logical: nerve and eye tissue develop from the same cells.

Understanding the cytokine’s role may be valuable in diagnosis and treatment.

In most eyes, the mask reduced or resolved cysts in the OCT subfield.

A 12-tube polymerase chain reaction strip can detect 24 ocular pathogens.

Annual rate of ocular inflammatory flares fell from 200 to 49 per 100 patients.

Researchers find gap in antioxidant enzymes between AMD patients and controls.

Whether injected monthly or according to a TREX regimen, ranibizumab did not have a statistically significant effect on the development of new macular atrophy in eyes with neovascular AMD.

The FDA’s decision follows the EU’s decision last month to similarly expand the scope of the drug’s approval to include more specific causes of vision loss and blindness.

At the one-month follow-up exam, only 7% were functional non-responders, half of whom were reclassified as responders at 6-month follow-up.